Abstract
Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Keywords: calcitriol, cancer, microRNA, vitamin D.
Current Gene Therapy
Title:Vitamin D and miRNAs in Cancer
Volume: 14 Issue: 4
Author(s): Yingyu Ma, Donald L. Trump and Candace S. Johnson
Affiliation:
Keywords: calcitriol, cancer, microRNA, vitamin D.
Abstract: Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Export Options
About this article
Cite this article as:
Ma Yingyu, Trump L. Donald and Johnson S. Candace, Vitamin D and miRNAs in Cancer, Current Gene Therapy 2014; 14 (4) . https://dx.doi.org/10.2174/1566523214666140612153537
DOI https://dx.doi.org/10.2174/1566523214666140612153537 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer
Current Chemical Biology The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research High Anti-cancer Activity, Low Animal Toxicity, and Structure Activity Relationships of Curcumin Analogs
Letters in Drug Design & Discovery Platelet Biomarkers in Tumor Growth
Current Proteomics Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi
Current Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design